Overview

A Study of Pyridostigmine in Postural Tachycardia Syndrome

Status:
Recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.

Phase:

N/A

Details

Lead Sponsor:

Mayo Clinic

Collaborator:

National Institutes of Health (NIH)

Treatments:

Pyridostigmine Bromide